FLT3 as a therapeutic target in AML: still challenging after all these years
about
Oxidative stress responses and NRF2 in human leukaemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaA pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivoBET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsRole of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cellsSecondary mutations as mediators of resistance to targeted therapy in leukemiaFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsEvaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerH2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Relapsed acute myeloid leukemia: why is there no standard of care?Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivoC/EBPα and MYB regulate FLT3 expression in AMLSU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cellsFunctional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational statusPacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cellsFlt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.Randomized phase II trials: a long-term investment with promising returnsFLT3/ITD AML and the law of unintended consequences.p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AMLDiscovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cellsTranscriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiaGold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Renal cell neoplasms contain shared tumor type-specific copy number variations.
P2860
Q26864239-6ED7059C-14C5-440D-B4BF-2BFE6FE87177Q27027207-42612EF8-38F3-418C-A6B6-F062706467FFQ27028163-E5E4CDBA-5D4A-4E52-9499-EED48E3260F8Q27674324-221867DF-C673-4E36-B436-8E551705A656Q27684428-C2B02FCA-22B4-4097-ADCB-834BD670C1F2Q28066765-F64C6A6A-09BC-45F8-A74E-E6A2327C9B5EQ28081494-8FC5B332-7C6B-4F62-9B27-4BDCC5F43AB0Q28087213-FAF4EC65-C712-443C-B9D9-7157ED745281Q28289859-29A3CB18-C826-45B2-A8AA-D4B6C0E516AEQ28481327-54D33CD3-4B2C-4A95-816A-89165AB79D74Q28538435-A9F1CC34-9DD8-43C9-80A0-00C083846F8CQ31074393-09EFD135-6B22-48F9-AD95-348C53E18B7EQ33749036-D9F79778-35F2-4087-AF9F-43324498B0ABQ33767026-760764E3-1556-4F23-8148-B99C2535B177Q33877202-77CC3DBD-C2AB-4A50-B965-1BB88936270FQ34011740-04BABAF1-E3AB-478A-846F-5D04C5A6ADE7Q34238553-FC8B4660-0E8F-4C79-A68B-9735293CE4EAQ34289202-0B7A897B-C2E3-40EA-B1B7-6F72498CAB56Q34320769-8D5C76CB-8053-4ED6-B9CF-9CB166A039A8Q34425939-5AC2B5DB-8E50-48D5-8654-C83F24DE230AQ34502608-32A8419A-C4DD-48DB-9A79-B96EE713FAB6Q34595162-783B8C83-2BD3-4959-BCAF-86F1786556D1Q34640779-71D32AF5-A639-44E2-861F-9341C612C29FQ34805329-48F7AA78-A790-4C3B-B9A8-CAC912F23DDDQ34973744-13E29DBA-2F35-4303-B129-BC4DEEE71C0DQ35009327-4A648581-B087-4D50-B9E3-0F877FF99B59Q35048469-43A287DE-6271-40D9-B441-E7D1A88F1119Q35115259-37002EDE-E8D6-41B0-B9D9-E38EFC8738F3Q35127958-43F9B585-DBD7-417F-B639-08593F46F130Q35485832-0C59C959-47C5-4784-B967-8D63B511470AQ35525811-5A271EBB-6FA1-44EC-A056-EF2005C88502Q35560182-95E19B95-C4C7-4796-8B7B-A5496DD22851Q35739494-B87CDD33-04D0-4266-87A1-134176D789A3Q35747414-D40EDA00-C6FE-4FF5-8A5A-482863E39620Q35800581-E7C1D65C-DC29-499E-856D-29EE294182E3Q35865681-22277640-422A-42FD-8E65-CED64CE81B14Q35922032-DAF25255-77F0-41BC-B844-2E23218E70DBQ35940547-0D468579-5A68-44AB-9188-0E7A3B2BDD30Q35979385-67F70A85-C660-4BDD-87FB-F99B21AA1492Q36044617-0CE1C3C5-B2BB-46D6-8E3D-3632F5309534
P2860
FLT3 as a therapeutic target in AML: still challenging after all these years
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FLT3 as a therapeutic target in AML: still challenging after all these years
@ast
FLT3 as a therapeutic target in AML: still challenging after all these years
@en
type
label
FLT3 as a therapeutic target in AML: still challenging after all these years
@ast
FLT3 as a therapeutic target in AML: still challenging after all these years
@en
prefLabel
FLT3 as a therapeutic target in AML: still challenging after all these years
@ast
FLT3 as a therapeutic target in AML: still challenging after all these years
@en
P3181
P1433
P1476
FLT3 as a therapeutic target in AML: still challenging after all these years
@en
P2093
Thomas Fischer
Thomas Kindler
P304
P3181
P356
10.1182/BLOOD-2010-04-261867
P407
P577
2010-08-12T00:00:00Z